S_mnary Topoisomerase II is a key target for several anti-cancer drugs used for breast cancer therapy, including doxorubicin, epirubicin and mitoxantrone. Two isoforms of topoisomerase II (x and /) have been described in human cells which differ in their subcellular localisation, biochemical properties and susceptibility to inhibition by anti-cancer drugs. The relative level of expression of the x and isoforms may contribute to the degree of tumour responsiveness to different chemotherapeutic agents. To assess the relationship between expression of topoisomerase II isoforms and established prognostic factors and pathological variables, 56 primary breast tumour samples were studied. The expression of the two topoisomerase II genes was apparently not co-ordinately regulated in these tissue samples. There was no relationship between any of the commonly used pathological variables [tumour size, lymph node status, S-phase fraction (SPF)] and the level of expression of topoisomerase II mRNA. However, high topoisomerase 112 gene expression was significantly associated with a high SPF (sign-rank test; P=0.01). Moreover, the ratio of mRNA levels for topoisomerase I12 and showed a stronger relationship to SPF (median ratio 0.62 for tumours with SPF 10, and 1.64 for SPF> 10; P=0.0021, sign-rankl test). As expected from previous studies, an SPF> 10 was associated with poor overall survival (P=0.01). Immunohistochemical analysis revealed that topoisomerase II was widely distributed (>90% positive tumour cells), but that topoisomerase H2 expression was less widely expressed, with a pattern of expression similar to that of the proliferation-dependent antigen recognised by Ki67. Because topoisomerase II gene expression showed a log-normal distribution, log-transformed data were used in multivariate analysis of relapse-free survivaL This showed that lymph node status and topoisomerase II mRNA expression were the only significant survival factors (P=0.001 and 0.05, respectively, with relative risks of 1.3 and 1.8). These results indicate that topoisomerase W1, but not /3, expression is dependent upon cellular proliferation status, but that the more widely expressed topoisomerase II protein may play a significant role as a target for antitumour therapy.
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Keywords topoisomerase 112; topoisomerase II; breast cancer, S-phase fraction There is an extensive body of work detailing the potential value of prognostic markers in breast cancer. The major objective of such studies is to separate patients into low-and high-risk categories permitting effort to be concentrated on those patients in the latter category. Such an approach has been found useful in determining the benefits of chemotherapy, such as the combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF), in patients with affected regional lymph nodes (Early Breast Cancer Thallists' Group, 1992) . The standard prognostic indices that have been assessed in node-negative breast cancer are tumour size, histological classification, nuclear grade, oestrogen and progesterone receptor status, DNA ploidy and S-phase fraction (SPF; reviewed by McGuire and Clark, 1992) . There is also evidence that cathepsin D levels, epidermal growth factor receptor (EGFR) status and the presence of the HER/neu oncogene may be of some prognostic value (reviewed by Gasparini et al., 1993) . Recently, expression of p53 protein has been shown to be associated with a high tumour proliferation rate, early disease recurrence and early death in node-negative breast cancer patients (Allred et al., 1993) . In addition to the identification of prognostic factors, there is a clear need for predictive markers that will permit both the development of more appropriate adjuvant chemotherapy and the selection of those patients most likely to respond to a particular drug regimen.
A potential prognostic indicator that could also be predictive of response to chemotherapy is the level of expression of topoisomerase II. This essential nuclear enzyme is the primary cellular target for several of the most effective anti-tumour agents including doxorubicin, etoposide, epirubicin and mitoxantrone (reviewed by Smith, 1990; Osheroff et al., 1991; Beck et al., 1993; Pommier, 1993; Watt and Hickson, 1994) . Topoisomerases catalyse the interconversion of topological isomers of DNA. The type II topoisomerases, such as topoisomerase II, act via the introduction of a transient double-stranded break in one segment of a DNA molecule through which a second DNA duplex is passed before religation of the break. In mammalian cells, a role for topoisomerase II has been suggested in DNA replication, recombination and possibly transcription, as well as in mitotic chromosome condensation and segregation (reviewed by Osheroff et al., 1991; Wang, 1985; Watt and Hickson, 1994) . Topoisomerase II is also a structural component of the interphase nucleus, possibly anchoring looped domains of chromatin to the nuclear scaffold or matrix (Earnshaw et al., 1985; reviewed by Roberge and Gasser, 1992) .
Topoisomerase II protein levels are markedly higher in exponentially growing than in quiescent cell lines in tissue culture, and can be down-regulated by growth of cells at high density or in serum-free conditions (Hsiang et al., 1988) . Thus, topoisomerase II may be regarded as a marker of cell proliferation. Moreover, cells induced to differentiate show progressively reduced levels of topoisomerase II activity (Constantinou et al., 1989; Zwelling et al., 1990) .
Two distinct isoforms of topoisomerase II exist in human cells, termed x (170 kDa form) and (180 kDa form), which differ not only in molecular weight but also in their patterns of expression and their apparent sensitivity to anti-neoplastic drugs Chung et al., 1989; Woessner et (PHA) show increased expression of both the x and / isoforms (Kaufmann et al., 1994; Prosperi et al., 1994 Chomczynski and Sacchi, (1987) . RNA concentration was quantified by measurement of optical density at 260 nm. Integrity of RNA was assessed by running samples on 1% agarose gels followed by staining with ethidium bromide.
Ribonuclease protection assays Ribonuclease protection assays were carried out as described by Jenkins et al. (1992) . Topoisomerase IIb and / antisense RNA probes were prepared as described previously (Davies et al., 1993) . The topoisomerase 112-and #-specific probes generated 215 bp and 228/292 bp (two splice variants termed /3-1 and /-2) protected fragments respectively. In each reaction an internal loading control of an antisense transcript to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used (producing a 120 bp protected fragment). Quantification of image intensities and autoradiograms was performed using a Bio-Image analyser (MilliGen/ BioSearch).
DNA flow cvtometrv
Nuclei were extracted from a 50 pm paraffin-embedded tissue section for each tumour as described previously (Camplejohn et al., 1989) . Briefly, each section was dewaxed, rehydrated and was treated for 30 min at 3TC with pepsin, pH 1.5.
Debris was removed by filtration through a 35 pm pore size nylon gauze and the nuclei were stained with a DNA-specific dye DAPI at a concentration of I pg ml-'. DNA There was no correlation (P>0.05) between the relative levels of the topoisomerase Ilz and f mRNAs in individual tumours (Figure 2) . Thus, in some samples with low levels of topoisomerase I12 mRNA, there were equivalently low levels of topoisomerase IlI mRNA (such as sample 9; Figure 1 ), whereas in other cases with low topoisomerase Ilz mRNA expression, the level of topoisomerase HfI mRNA was substantially higher (sample 6; Figure 1 ). The relative level of the fl-I and f-2 mRNAs was generally constant in each sample.
Relation to topoisomerase II mRNA to SPF and ploidy The tumours were studied with respect to the relationship between topoisomerase H mRNA expression and SPF. Those cases with a high SPF (defined as being >10%) showed significantly higher topoisomerase Ili mRNA that those with a low SPF (< 10%) (median 1.47 and 0.42 respectively, using the Mann -Whitney U-test for non-parametric samples; P=0.01 level). Because the data was log-normally distributed, the Spearman rank correlation coefficient for logtopoisomerase Ili vs SPF was performed (Figure 3) , and showed a correlation coefficient of 0.33 (P=0.01). Using the median densitometric value of 1 to separate the cases on the basis of topoisomerase Ila mRNA content, it was found that SPF was significantly higher in those with topoisomerase Ila values above the median (P= 0.03; Fisher's exact test). However, there was no relationship between SPF and the level of the topoisomerase IlI mRNA or log topoisomerase II#f mRNA (data not shown). The SPF was more highly related to the ratio of topoisomerase Ili to f mRNA than to topoisomerase Hzx mRNA level alone (Figure 4) Wang, 1985; Roberge and Gasser, 1992; Watt and Hickson, 1994) . However, there was no correlation between tumour ploidy and expression of either isozyme. Moreover, there was also no correlation between levels of topoisomerase II and either hormone receptor status or tumour size. In our study, the levels of the two topoisomerase II isoforms varied significantly between different tumours with a more than 200-fold variation in expression between the highest and lowest expressors for each isozyme. Despite this, no pattern was found which might suggest that the topoisomerase HIz and / genes are coordinately regulated in breast tumours. Indeed, Jenkins et al. (1992) (Smith et al., 1993) . Amplification of the topoisomerase Ili locus was not found. In the cultured cell line SKBr-3, amplification of erbB-2 was also associated with topoisomerase IlI amplification; this line also showed increased sensitivity to the topoisomerase II inhibitors m-AMSA and mitoxantrone. These examples indicate that an increase in topoisomerase II mRNA could reflect genetic changes within a tumour (Keith et al., 1993) .
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